Txn1, Ctsd and Cdk4 are key proteins of combination therapy with taurine, epigallocatechin gallate and genistein against liver fibrosis in rats
Txn1, Ctsd and Cdk4 are key proteins of combination therapy with taurine, epigallocatechin gallate and genistein against liver fibrosis in rats
复制标题
Txn1、Ctsd 和 Cdk4 是牛磺酸、表没食子儿茶素没食子酸酯和金雀异黄素联合治疗大鼠肝纤维化的关键蛋白
DOI：
10.1016/j.biopha.2016.11.071
复制
发表时间：
2017-01-01
影响因子：
7.5
通讯作者：
Liao, Ming
中科院分区：
文献类型：
--
作者：
Cao, Wen;Li, Yan;Liao, Ming
本课题组前期工作从血清蛋白质组学角度研究了牛磺酸、表没食子儿茶素没食子酸酯和染料木素联合治疗的抗肝纤维化作用机制。为了进一步研究和系统分析联合用药抗肝纤维化的其他可能机制，采用异序标记相对和绝对定量（iTRAQ）蛋白质组学方法，研究联合用药后四氯化碳诱导的肝纤维化大鼠肝组织蛋白质谱的变化。共鉴定了115个差异表达蛋白，其中包含84个上调蛋白和31个下调蛋白。筛选出3个与抗氧化防御系统和肝星状细胞活化增殖相关的差异表达蛋白（Txn1、Ctsd和Cdk4），并通过Western blot和实时荧光定量PCR进行验证。我们的研究强调了差异表达蛋白Txn 1、Ctsd和Cdk 4对肝纤维化的重要性，这可能为阐明联合治疗作为治疗肝纤维化的潜在药物的作用提供更准确和全面的观点。(C)2016 Elsevier Masson SAS。All rights reserved.
The anti-fibrotic mechanism of combination therapy with taurine, epigallocatechin gallate and genistein was studied from the perspective of serum proteomics in our previous work. In order to further investigate and systematically analyse other possible therapeutic mechanism of combination therapy against liver fibrosis, isobaric tags for relative and absolute quantification (iTRAQ) proteomic analysis was applied to study the protein profile changes in liver tissue of carbon tetrachloride-induced liver fibrosis rats after combination therapy. A total of 115 differentially expressed proteins containing 84 up-regulated and 31 down-regulated proteins in response to combination therapy were identified. Three differentially expressed proteins (Txn1, Ctsd and Cdk4) involved in antioxidant defense system and the activation and proliferation of hepatic stellate cell were selected for further validation by western blot and real-time PCR analysis. Our study highlight the importance of differentially expressed proteins Txn1, Ctsd and Cdk4 against liver fibrosis, which may provide a more precise and comprehensive perspective for clarifying the roles of combination therapy as a potential agent for treatment of liver fibrosis. (C) 2016 Elsevier Masson SAS. All rights reserved.